Argenx Se (ARGX) EBT Margin Growth (3y) (2019 - 2026)

Argenx Se (ARGX) EBT Margin Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9,237.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -408.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -120.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 7,297.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -120.00
Dec 31, 2025 758.00
Sep 30, 2025 -14,927.00
Jun 30, 2025 93,509.00
Mar 31, 2025 -106,153.00
Dec 31, 2024 95,243.00
Sep 30, 2024 1,534.00
Jun 30, 2024 16,384.00
Mar 31, 2024 -17.00
Dec 31, 2023 1.40 Mn
Sep 30, 2023 35,446.00
Jun 30, 2023 12,760.00
Mar 31, 2023 44,680.00
Dec 31, 2022 130,146.00
Sep 30, 2022 -108,073.00
Jun 30, 2022 -17,451.00
Mar 31, 2022 106,813.00
Dec 31, 2021 -62,539.00
Sep 30, 2021 -29,948.00
Jun 30, 2021 -15,461.00